Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
暂无分享,去创建一个
A. Cohen-Solal | G. Filippatos | A. Mebazaa | L. Lund | J. Cleland | M. Metra | A. Bayés‐Genís | P. Seferovic | G. Rosano | M. Piepoli | S. Adamopoulos | A. Coats | F. Braunschweig | A. Ristic | M. Volterrani | M. Böhm | G. Savarese | S. von Haehling | M. Yılmaz | W. Mullens | T. Gal | L. Hill | K. Damman | F. Gustafsson | C. Tocchetti | C. Vitale | M. Adamo | O. Chioncel | D. Tomasoni | S. Anker | Rajan Sharma | B. Moura | T. McDonagh | M. Abdelhamid | L. Antohi | J. Butler | A. Rakisheva | E. Jankowska | P. Ponikowski | M. Lainščak
[1] N. Dau,et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. , 2023, The New England journal of medicine.
[2] G. Filippatos,et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology , 2023, European journal of heart failure.
[3] W. Abraham,et al. Transcatheter interventions for heart failure. , 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[4] D. Morrow,et al. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/valsartan versus Valsartan in HFmrEF and HFpEF with a Worsening Heart Failure Event. , 2023, Journal of cardiac failure.
[5] K. Anstrom,et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. , 2023, JAMA.
[6] L. Allen,et al. Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice , 2023, European journal of heart failure.
[7] A. Pandey,et al. Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial. , 2023, JAMA cardiology.
[8] L. Lund,et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. , 2023, Journal of the American College of Cardiology.
[9] M. Metra,et al. Aiming at harmony. Comparing and contrasting International HFrEF Guidelines , 2022, European heart journal supplements : journal of the European Society of Cardiology.
[10] M. Senni,et al. Practical Patient Care Considerations with Use of Vericiguat After Worsening Heart Failure Events. , 2022, Journal of cardiac failure.
[11] A. Mebazaa,et al. Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? , 2022, European heart journal.
[12] F. Formiga,et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. , 2022, European heart journal.
[13] R. McKelvie,et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. , 2022, The New England journal of medicine.
[14] K. Sliwa,et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial , 2022, The Lancet.
[15] C. Angermann,et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial , 2022, European heart journal.
[16] K. Anstrom,et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum , 2022, European journal of heart failure.
[17] L. Steiner,et al. Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes , 2022, European journal of heart failure.
[18] N. Samani,et al. Albuminuria as a marker of systemic congestion in patients with heart failure , 2022, European heart journal.
[19] N. Girerd. Worsening renal function precedes and follows worsening heart failure , 2022, European journal of heart failure.
[20] A. Cohen-Solal,et al. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology , 2022, European journal of heart failure.
[21] Akshay S. Desai,et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.
[22] G. Filippatos,et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. , 2022, The New England journal of medicine.
[23] F. Burzotta,et al. Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis , 2022, European journal of heart failure.
[24] J. McMurray,et al. Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction. , 2022, Circulation. Heart failure.
[25] Akshay S. Desai,et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. , 2022, Journal of the American College of Cardiology.
[26] M. Pfeffer,et al. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial , 2022, European journal of heart failure.
[27] G. Filippatos,et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial , 2022, European journal of heart failure.
[28] A. Go,et al. Analysis of Worsening Heart Failure Events in an Integrated Health Care System. , 2022, Journal of the American College of Cardiology.
[29] I. Ranasinghe,et al. Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand , 2022, European journal of heart failure.
[30] G. Filippatos,et al. Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. , 2022, JACC. Heart failure.
[31] D. Kitzman,et al. Intervention Adherence in REHAB‐HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events , 2022, Journal of the American Heart Association.
[32] G. Filippatos,et al. Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. , 2022, JACC. Heart failure.
[33] E. Gronda,et al. Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial". , 2022, Circulation.
[34] N. Mewton,et al. Practical outpatient management of worsening chronic heart failure , 2022, European journal of heart failure.
[35] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[36] K. Anstrom,et al. Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial , 2022, European journal of heart failure.
[37] Ò. Miró,et al. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology , 2022, European journal of heart failure.
[38] P. Ponikowski,et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.
[39] L. Lund,et al. Global burden of heart failure: A comprehensive and updated review of epidemiology. , 2022, Cardiovascular research.
[40] K. Dickstein,et al. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry , 2022, European journal of heart failure.
[41] J. Butler,et al. Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. , 2022, Journal of cardiac failure.
[42] G. Filippatos,et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Registry , 2021, European journal of heart failure.
[43] J. Cleland,et al. Worsening renal function in acute heart failure in the context of diuretic response , 2021, European journal of heart failure.
[44] G. Fonarow,et al. In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable , 2021, European journal of heart failure.
[45] José Miguel Contreras,et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. , 2021, The lancet. Diabetes & endocrinology.
[46] Neha J. Pagidipati,et al. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. , 2021, Journal of the American College of Cardiology.
[47] J. H. Patterson,et al. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry , 2021, Circulation. Heart failure.
[48] G. Filippatos,et al. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. , 2021, Journal of the American College of Cardiology.
[49] J. McMurray,et al. Head‐to‐head comparison of contemporary heart failure risk scores , 2021, European journal of heart failure.
[50] A. Mebazaa,et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC) , 2021, European journal of heart failure.
[51] J. Cleland,et al. To master heart failure, first master congestion , 2021, The Lancet.
[52] Akshay S. Desai,et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial , 2021, The Lancet.
[53] J. Lupón,et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review , 2021, European journal of heart failure.
[54] P. Ponikowski,et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF , 2021, European journal of heart failure.
[55] Sanjiv J. Shah,et al. Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations , 2021, European journal of heart failure.
[56] Akshay S. Desai,et al. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. , 2021, JACC. Heart failure.
[57] P. Ponikowski,et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. , 2021, Journal of cardiac failure.
[58] L. Lund,et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019 , 2021, European journal of heart failure.
[59] G. Felker,et al. Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States. , 2021, Journal of the American College of Cardiology.
[60] P. Ponikowski,et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.
[61] G. Fonarow,et al. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. , 2021, JAMA cardiology.
[62] J. Butler,et al. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. , 2021, Circulation.
[63] A. Mebazaa,et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades , 2021, European journal of heart failure.
[64] G. Filippatos,et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.
[65] G. Koch,et al. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF , 2020, European journal of heart failure.
[66] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[67] K. Sliwa,et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. , 2020, JAMA cardiology.
[68] P. Ponikowski,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.
[69] G. Hindricks,et al. In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network , 2020, European journal of heart failure.
[70] S. Solomon,et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart , 2020, European journal of heart failure.
[71] I. Ranasinghe,et al. Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand , 2020, European journal of heart failure.
[72] S. Anker,et al. Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study , 2020, European journal of heart failure.
[73] H. Ross,et al. REDUCED RATE OF HOSPITAL PRESENTATIONS FOR HEART FAILURE DURING THE COVID-19 PANDEMIC IN TORONTO, CANADA , 2020, Canadian Journal of Cardiology.
[74] Akshay S. Desai,et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction , 2020, Circulation.
[75] Irfan Ahmed Rind,et al. Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London , 2020, European journal of heart failure.
[76] N. Samani,et al. Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF , 2020, European journal of heart failure.
[77] T. Biering-Sørensen,et al. One‐Year Mortality After Intensification of Outpatient Diuretic Therapy , 2020, Journal of the American Heart Association.
[78] W. Wijns,et al. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first‐in‐human study , 2020, European journal of heart failure.
[79] J. Lindenfeld,et al. Decreases in acute heart failure hospitalizations during COVID‐19 , 2020, European journal of heart failure.
[80] J. Ruidavets,et al. Telemonitoring versus standard care in heart failure: a randomised multicentre trial , 2020, European journal of heart failure.
[81] M. Metra,et al. Acute heart failure: More questions than answers. , 2020, Progress in cardiovascular diseases.
[82] J. McMurray,et al. Readmission and death in patients admitted with new‐onset versus worsening of chronic heart failure: insights from a nationwide cohort , 2020, European journal of heart failure.
[83] Akshay S. Desai,et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy , 2020, European heart journal.
[84] K. Anstrom,et al. Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. , 2020, Circulation.
[85] P. Ponikowski,et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.
[86] M. Metra,et al. Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis. , 2020, JACC. Heart failure.
[87] C. Morgan,et al. Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. , 2020, The American journal of medicine.
[88] A. Mebazaa,et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.
[89] G. Filippatos,et al. Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.
[90] P. Ponikowski,et al. Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry , 2019, European journal of heart failure.
[91] K. Khunti,et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study , 2019, The Lancet. Public health.
[92] J. Cleland,et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure , 2019, European journal of heart failure.
[93] G. Filippatos,et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.
[94] R. Arena,et al. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[95] Akshay S. Desai,et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.
[96] N. Samani,et al. Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure , 2019, European journal of heart failure.
[97] Mahesh J. Patel,et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.
[98] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[99] G. Filippatos,et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.
[100] M. Emdin,et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. , 2018, Journal of the American College of Cardiology.
[101] Manesh R. Patel,et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF , 2018, European heart journal.
[102] K. Dickstein,et al. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT‐CHF study , 2018, European journal of heart failure.
[103] Davor Milicic,et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.
[104] Y. Pinto,et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) , 2018, Circulation.
[105] Rui Placido,et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion , 2018, European journal of heart failure.
[106] G. Felker,et al. Outpatient Worsening Heart Failure as a Target for Therapy: A Review , 2018, JAMA cardiology.
[107] A. Mebazaa,et al. Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. , 2017, JACC. Heart failure.
[108] K. Anstrom,et al. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.
[109] R. Matsukawa,et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. , 2017, Journal of the American College of Cardiology.
[110] J. McMurray,et al. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review , 2017, European journal of heart failure.
[111] Finn Gustafsson,et al. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes , 2017, European journal of heart failure.
[112] A. Mebazaa,et al. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. , 2017, JACC. Heart failure.
[113] Adrian F. Hernandez,et al. Acute Heart Failure: Alternatives to Hospitalization. , 2017, JACC. Heart failure.
[114] Akshay S. Desai,et al. Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. , 2016, JACC. Heart failure.
[115] S. Solomon,et al. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.
[116] Susan Cheng,et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. , 2016, European heart journal.
[117] P. Ponikowski,et al. In‐hospital worsening heart failure , 2015, European journal of heart failure.
[118] A. Bardají,et al. A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin‐SCORE , 2015, European journal of heart failure.
[119] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[120] E. Braunwald,et al. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. , 2014, JAMA.
[121] K. Doran,et al. Abstract 204: Emergency Department Visits for Heart Failure and Subsequent Hospitalization or Observation Unit Admission , 2014 .
[122] W. Self,et al. The burden of acute heart failure on U.S. emergency departments. , 2014, JACC. Heart failure.
[123] M. Slaughter,et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). , 2014, Journal of the American College of Cardiology.
[124] S. Solomon,et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT , 2014, European journal of heart failure.
[125] Naoki Sato,et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.
[126] P. Ponikowski,et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.
[127] C. Yancy,et al. Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. , 2013, Journal of the American College of Cardiology.
[128] G. Filippatos,et al. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. , 2012, European heart journal.
[129] M. Metra,et al. Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?: The Role of Congestion and Its Interaction With Renal Function , 2012, Circulation. Heart failure.
[130] M. Borggrefe,et al. Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure , 2011, Circulation.
[131] P. Ponikowski,et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study , 2011, European heart journal.
[132] A. Boyle,et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[133] L. Stevenson,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.
[134] M. Zile,et al. Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.
[135] J. Concato,et al. Patterns of Weight Change Preceding Hospitalization for Heart Failure , 2007, Circulation.
[136] H. Tsutsui. [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[137] J. Rouleau,et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.
[138] N. Hollenberg,et al. Literature alert , 2002 .
[139] S. Russell,et al. Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. , 2018, JACC. Heart failure.
[140] Christopher M. O'Connor,et al. Pathophysiology and clinical evaluation of acute heart failure , 2016, Nature Reviews Cardiology.
[141] Akshay S. Desai,et al. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit. , 2016, JACC. Heart failure.
[142] G. Fonarow,et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2007, American heart journal.